These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 18076209)

  • 1. ADP receptor antagonism: what's in the pipeline?
    Angiolillo DJ
    Am J Cardiovasc Drugs; 2007; 7(6):423-32. PubMed ID: 18076209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Myocardial infarction: Role of new antiplatelet agents].
    Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
    Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Cattaneo M
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
    Dovlatova NL; Jakubowski JA; Sugidachi A; Heptinstall S
    J Thromb Haemost; 2008 Jul; 6(7):1153-9. PubMed ID: 18485086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
    Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
    Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
    Savi P; Herbert JM
    Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New P2Y12 blockers.
    Cattaneo M
    J Thromb Haemost; 2009 Jul; 7 Suppl 1():262-5. PubMed ID: 19630813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
    Raju NC; Eikelboom JW; Hirsh J
    Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New anti-platelet agents: the end of resistance?
    Kastrati A
    Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging P2Y12 receptor antagonists: role in coronary artery disease.
    Oliphant CS; Doby JB; Blade CL; Das K; Mukherjee D; Das P
    Curr Vasc Pharmacol; 2010 Jan; 8(1):93-101. PubMed ID: 19485932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
    Cattaneo GJ; Podda GM; Cattaneo M
    Recenti Prog Med; 2011 Apr; 102(4):150-5. PubMed ID: 21572491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
    Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.